---
figid: PMC9497187__cancers-14-04496-g001
figtitle: Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple
  Positive and Triple Negative Breast Cancer Cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9497187
filename: cancers-14-04496-g001.jpg
figlink: /pmc/articles/PMC9497187/figure/cancers-14-04496-f001/
number: F1
caption: (A) Schematic showing the sphingolipid metabolic pathway where serine palmitoyl
  transferase (SPT1–2), 3–Ketosphinganine reductase (KDSR), Dihydroceramide desaturase
  (DEGS1–2), Ceramide synthases (CERS1–6), Ceramide transferase (CERT), Ceramide 1-phosphate
  phosphatase (C1PP), N–Acylsphingosine amidohydrolase (ASAH1, ASAH2), Alkaline ceramidase
  (ACER1, ACER3), Sphingosine–1–phosphate kinase (SPHK1, 2), Sphingosine–1–phosphate
  phosphatase (S1PP), Sphingosine–1–phosphate lyase (S1PL), Ceramide Kinase (CERK),
  Sphingomyelin Phosphodiesterase (SMPD1–4), Sphingomyelin synthase (SMS1–2), UDP-Glucose
  ceramide glucosyltransferase (UGCG), β–glucocerebrosidase (GBA1), β–galactosidase
  (GLB1), –1,4–Galactosyltransferase 6 (B4GALT6) are the enzymes of the pathway. (B)
  Schematic showing major subtypes of breast cancer, such as luminal A, luminal B,
  luminal B with HER2 overexpression (also called triple-positive, TPBC), triple-negative
  (TNBC)/Basal-like, and HER2+.
papertitle: Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple
  Positive and Triple Negative Breast Cancer Cells.
reftext: Kajal Rajput, et al. Cancers (Basel). 2022 Sep;14(18):4496.
year: '2022'
doi: 10.3390/cancers14184496
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: breast cancer | sphingolipids | triple-negative breast cancer | triple-positive
  breast cancer | ceramide-1-phosphate | siRNA delivery | localized therapy
automl_pathway: 0.8632427
figid_alias: PMC9497187__F1
figtype: Figure
redirect_from: /figures/PMC9497187__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9497187__cancers-14-04496-g001.html
  '@type': Dataset
  description: (A) Schematic showing the sphingolipid metabolic pathway where serine
    palmitoyl transferase (SPT1–2), 3–Ketosphinganine reductase (KDSR), Dihydroceramide
    desaturase (DEGS1–2), Ceramide synthases (CERS1–6), Ceramide transferase (CERT),
    Ceramide 1-phosphate phosphatase (C1PP), N–Acylsphingosine amidohydrolase (ASAH1,
    ASAH2), Alkaline ceramidase (ACER1, ACER3), Sphingosine–1–phosphate kinase (SPHK1,
    2), Sphingosine–1–phosphate phosphatase (S1PP), Sphingosine–1–phosphate lyase
    (S1PL), Ceramide Kinase (CERK), Sphingomyelin Phosphodiesterase (SMPD1–4), Sphingomyelin
    synthase (SMS1–2), UDP-Glucose ceramide glucosyltransferase (UGCG), β–glucocerebrosidase
    (GBA1), β–galactosidase (GLB1), –1,4–Galactosyltransferase 6 (B4GALT6) are the
    enzymes of the pathway. (B) Schematic showing major subtypes of breast cancer,
    such as luminal A, luminal B, luminal B with HER2 overexpression (also called
    triple-positive, TPBC), triple-negative (TNBC)/Basal-like, and HER2+.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SMPD2
  - SMPD1
  - SMPD3
  - SMPD4
  - SGMS2
  - SGMS1
  - CERS6
  - CERS2
  - CERS3
  - CERS1
  - GDF1
  - CERS4
  - CERS5
  - SPHK2
  - SPHK1
  - SPTLC1
  - SPTLC2
  - SPTY2D1
  - KDSR
  - ASAH1
  - DEGS1
  - DEGS2
  - CERT1
  - GBA1
  - CERK
  - UGCG
  - GLB1
  - B4GALT6
  - ERBB2
---
